Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYVIBE-005: MK-7684A (vibostolimab + pembrolizumab) with or without other anticancer therapies in selected solid tumors
jRCT2031210335Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of vibostolimab + pembrolizumab in Cervical Cancer (CC), endometrial cancer (EC), head and neck squamous cell carcinoma (HNSCC) and 12 more, sponsored by Merck & Co. Started Oct 2021; status: completed.
02
Drugs
vibostolimab + pembrolizumab
03
Conditions
Cervical Cancer (CC)endometrial cancer (EC)head and neck squamous cell carcinoma (HNSCC)biliary cancergallbladder cancer
Beyond the preview
Go deeper on jRCT2031210335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210335.